| Identification | Back Directory | [Name]
Riluzole | [CAS]
1744-22-5 | [Synonyms]
BF-37
RILUTEK
RILUZOLE
RP-54274
PK 26124
Rilutek (TN)
Prestwick-03A08
Riluzole(Rilutek)
Riluzole (200 mg)
BUTTPARK 13\02-09
CBI-BB ZERO/001785
Riluzole(GMPofSFDA)
Riluzole [USAN:INN]
Riluzolum [INN-Latin]
Riluzol [INN-Spanish]
Riluzole (JAN/USAN/INN)
RILUZOLE GLUTAMATE RELEASE INH
amino-2trifluoromethoxy-6benzothiazole
2-amino-6-trifluoromethoxy-benzothiazol
6-(trifluoromethoxy)-2-benzothiazolamin
6-trifluoromethoxy-2-aminobenzothiazole
6-(TRIFLUOROMETHOXY)-2-BENZOTHIAZOLAMINE
2-AMINO-6-(TRIFLUOROMETHOXY)BENZOTHIAZOLE
6-TRIFLUOROMETHOXY-BENZOTHIAZOL-2-YLAMINE
6--trifluoromethoxy-2(3H)-benzothiazolone
2-Benzothiazolamine, 6-(trifluoromethoxy)-
Benzothiazole, 2-amino-6-trifluoromethoxy-
6-TRIFLUOROMETHOXYBENZOTHIAZOLE-2-YL-AMINE
2-AMINO-6-(TRIFLUOROMETHOXYL)BENZOTHIAZOLE
6-(Trifluoromethoxy)benzo[d]thiazol-2-amine
2-Amino-6-(trifluoromethoxy)benzo[d)thiazole
6-(TRIFLUOROMETHOXY)-1,3-BENZOTHIAZOL-2-AMINE
2-Amino-6-(trifluoromethoxy)-1,3-benzothiazole
2-Amino-6-(trifluoromethoxy)-1,3-benzothiazole97%
[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amine
Amino-2 trifluoromethoxy-6 benzothiazole [French]
2-Amino-6-(trifluoromethoxy)-1,3-benzothiazole 97%
Riluzole, 6-(Trifluoromethoxy)-1,3-benzothiazol-2-amine
6-(Trifluoromethoxy)-2-benzothiazolamine, PK-26124, RP-54274, Rilutek | [EINECS(EC#)]
605-724-6 | [Molecular Formula]
C8H5F3N2OS | [MDL Number]
MFCD00210213 | [MOL File]
1744-22-5.mol | [Molecular Weight]
234.2 |
| Chemical Properties | Back Directory | [Appearance]
White Crystalline Solid | [Melting point ]
116-118°C | [Boiling point ]
296.3±50.0 °C(Predicted) | [density ]
1.572±0.06 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
DMSO: ≥25 mg/mL
| [form ]
solid
| [pka]
2.96±0.10(Predicted) | [color ]
white
| [Merck ]
14,8223 | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months. | [InChIKey]
FTALBRSUTCGOEG-UHFFFAOYSA-N |
| Hazard Information | Back Directory | [Chemical Properties]
White Crystalline Solid | [Usage]
A neuroprotective agent. A glutamate release inhibitor. An anticonvulsant | [Usage]
A neuroprotective agent. Modulates glutamatergic transmission. A glutamate release inhibitor. An anticonvulsant. | [Usage]
anticonvulsant, glutamate release inhibitor, anti-ALS | [Biological Activity]
Novel psychotropic agent with anticonvulsant, hypnotic, anxiolytic, anti-ischemic and anesthetic properties. Riluzole is able to act as a glutamate release inhibitor, blocks voltage-dependent Na + channels and inhibits GABA uptake by striatal synaptosomes. | [Originator]
Rhone-Poulenc Rorer (France) | [Uses]
A neuroprotective agent. A glutamate release inhibitor. An anticonvulsant | [Uses]
A neuroprotective agent. Modulates glutamatergic transmission. A glutamate release inhibitor. An anticonvulsant. | [Uses]
anticonvulsant, glutamate release inhibitor, anti-ALS | [Uses]
Labeled Riluzole, intended for use as an internal standard for the quantification of Riluzole by GC- or LC-mass spectrometry. | [Definition]
ChEBI: Riluzole is a member of benzothiazoles. | [Brand name]
Rilutek (Sanofi Aventis). | [Biochem/physiol Actions]
Glutamate release inhibitor; anticonvulsant | [storage]
Store at RT |
| Safety Data | Back Directory | [Hazard Codes ]
T,Xi | [Risk Statements ]
25 | [Safety Statements ]
45 | [RIDADR ]
UN 2811 6.1/PG 3
| [WGK Germany ]
3
| [RTECS ]
DL2830000
| [Hazard Note ]
Irritant | [HazardClass ]
IRRITANT | [PackingGroup ]
II | [HS Code ]
29342000 | [Toxicity]
LD50 in mice (mg/kg): 46 i.p.; 67 orally (Mizoule) |
| Questions And Answer | Back Directory | [Description]
Riluzole belongs to the derivative of benzothiazole with neuroprotective, potential anti-depressant and anxiolytic activities, which is used in the treatment of a certain type of nerve disease called amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). It is effective to delay the onset of ventilator-dependence or tracheostomy in selected patients, slow down the deterioration of this disease and probably prolong survival by approximately two to three months. Besides, studies have proved that riluzole has anti-depressant activity for refractory depression and serves as an anxiolytic in the treatment of obsessive-compulsive disorder and generalized anxiety disorder.
However, riluzole does not cure the ALS and reverse nerve damage or muscle weakness. It is believed to function as an inhibitor of a natural substance called glutamate. It helps protect the nerves in the brain and spinal cord from too much of glutamate which may contribute to the nerve damage. Riluzole is available in both tablet and liquid form. The liquid formulation may be more suitable for patients with swallowing difficulties.
| [References]
https://en.wikipedia.org/wiki/Riluzole
http://www.medicinenet.com/riluzole_oral_tablets/article.htm
https://pubchem.ncbi.nlm.nih.gov/compound/5070#section=Top
|
|
|